Tricking The Brain’s Border Patrol

Unlocking new therapeutics by messing with the brain’s strictest barrier

By Negin Imani & Amirali Banani

The blood-brain barrier (BBB) doesn’t play around. Other than some tiny, lipid-soluble molecules and vital nutrients needed for neural cell function such as oxygen and glucose can cross without assistance. Certain medications like alcohol and anesthetics can also cross with the help of transport proteins.

When administering drugs for therapeutic purposes to the brain, they get easily rejected and are rendered useless. But researchers today are devising new ways to trick this barrier to allow these drugs to diffuse across the membrane. In this article, we’ll be covering a few of the ways by which these drugs are able to trick the BBB and their potential for helping cure some of the most daunting neurological diseases.

In disguise…

The most common method for a drug to trick the BBB is to disguise itself as a molecule that the barrier lets in — called the “Trojan horse” therapeutic. Take L-DOPA (levodopa), a drug used to treat Parkinson’s that mimics an amino acid that easily crosses the BBB and is transported by LAT-1 (used to shuttle large amino acids into the brain through the BBB). [1] After disguising itself as an amino acid to cross the BBB, L-DOPA gets converted into dopamine in the brain where it exerts its effects of increasing dopamine levels in the patient.

In this case, the drug resembles typical nutrients that can cross the BBB before getting converted back into its active form once in the brain. Smart right?

“Trojan horse” approach

The Trojan horse approach is receptor-mediated, as drugs are fused to molecules that bind to transport receptors (such as insulin or transferrin receptors) located on the BBB. A prime example for this is fusion proteins such as monoclonal antibodies that are linked to a peptide drug and bind to a transferrin receptors, allowing the drug to be actively transported into the brain. [2] This approach is special in that it doesn’t disrupt or weaken the BBB in any way, but rather exploits the brain’s existing transport systems, mimicking natural ligands like lipoproteins and “riding along” with them (like a Trojan horse) to deliver antibodies, peptides, enzymes, or even gene therapies into the brain — an incredibly innovative area for treatment being explored rigorously.

Nanoparticles in disguise

A new approach being explored is nanoparticle-based carriers, in which therapeutic drugs are enclosed in or attached to nanoparticles that are coated with substances the BBB recognizes, allowing these drugs to cross the BBB and once again trick the barrier into thinking it’s a molecule that should be permitted to cross into the brain. A few examples include:

• Lipid nanoparticles, which are typically used in mRNA delivery, now being engineered to selectively cross the BBB [3[
• Exosomes, membrane-bound extracellular vesicles, that naturally cross the BBB and can carry RNA or drugs across [4]
• Polysorbate 80-coated nanoparticles…these bind to low-density lipoprotein (LDL) receptors and mimic lipoproteins that can cross the BBB [5]

Breaking the Barrier for Alzheimer’s: Turning Innovation into Therapy

For years, Alzheimer’s disease has stood as one of the hardest puzzles in neuroscience. The main reason is simple but frustrating: most potential drugs never reach their targets inside the brain because the BBB stops them along the way. Researchers have tried countless approaches, yet many failed for the same reason. Now, the same mechanisms once thought of as clever “tricks” to cross the BBB are beginning to take shape as realistic therapeutic options for Alzheimer’s. [6]

Opening the Barrier with Sound

One particularly creative approach uses focused ultrasound (FUS) together with tiny microbubbles. When applied to specific brain regions, this technique gently and temporarily loosens the BBB, letting medications pass through. It is a precise and reversible process, which means the barrier restores itself soon after. In several recent studies, FUS has shown the ability to improve how anti-amyloid antibodies reach the brain and help clear toxic plaque deposits. The findings are early, but they point to a safer and more targeted way of delivering Alzheimer’s treatments than anything we have had before. [6]

Receptor-Mediated Transport: The Modern Trojan Horse

The receptor-mediated transcytosis (RMT) technique takes the idea of the Trojan horse and turns it into a medical tool. Instead of brute force, it relies on biological mimicry. Drugs are attached to familiar molecules such as transferrin or insulin that the BBB naturally allows inside. A prime example of this is Aducanumab, an antibody designed to target amyloid-β plaques. When engineered to bind to these receptors, it can “ride along” existing transport routes to enter the brain. [6]

Get Amirali Banani’s stories in your inbox

Join Medium for free to get updates from this writer.

Remember me for faster sign in

The strength of this approach lies in how naturally it fits within the body’s own systems rather than working against them.

Nanoparticles with Purpose

Another area gaining serious momentum involves nanoparticle-based drug delivery. Lipid and polymeric nanoparticles, and even gold nanoparticles coated with biological molecules, are being developed to carry peptides, RNA, or antibodies across the BBB.

What’s fascinating…unlike earlier methods, these nanosystems can actually be designed to recognize the molecular fingerprints of Alzheimer’s such as amyloid plaques or oxidative stress.

And what makes them especially remarkable is their dual role: they not only transport the drug but also protect it until it reaches its destination inside the brain. [7]

Looking ahead…

Together, these innovations signal a turning point in how we think about brain treatments. The aim is shifting away from fighting the BBB toward learning how to cooperate with it. If these methods continue to succeed, the BBB may no longer be seen as an obstacle but as an intelligent gatekeeper that, when approached wisely, can help deliver the very drugs once blocked by it.

References

1. Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, Shimohama S. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res. 2000 Oct 6;879(1–2):115–21. doi: 10.1016/s0006–8993(00)02758-x. PMID: 11011012.
2. Boado RJ. IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport. Pharmaceutics. 2022 Jul 15;14(7):1476. doi: 10.3390/pharmaceutics14071476. PMID: 35890374; PMCID: PMC9322584.
3. Wang C, Xue Y, Markovic T, Li H, Wang S, Zhong Y, Du S, Zhang Y, Hou X, Yu Y, Liu Z, Tian M, Kang DD, Wang L, Guo K, Cao D, Yan J, Deng B, McComb DW, Parsons RE, Minier-Toribio AM, Holt LM, Pan J, Hashemi A, Kopell BH, Charney AW, Nestler EJ, Peng PC, Dong Y. Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nat Mater. 2025 Oct;24(10):1653–1663. doi: 10.1038/s41563–024–02114–5. Epub 2025 Feb 17. PMID: 39962245; PMCID: PMC12514551.
4. Xiaopei Zhang, Nichole Artz, Dennis A. Steindler, Shawn Hingtgen, Andrew Benson Satterlee, Exosomes: Traversing the blood-brain barrier and their therapeutic potential in brain cancer, Biochimica et Biophysica Acta (BBA) — Reviews on Cancer, Volume 1880, Issue 3, 2025, 189300, ISSN 0304–419X, https://doi.org/10.1016/j.bbcan.2025.189300.
5. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001 Mar 23;47(1):65–81. doi: 10.1016/s0169–409x(00)00122–8. PMID: 11251246.
6. de Koning, L.A., et al. (2025). Drug delivery strategies to cross the blood-brain barrier in Alzheimer’s disease: a comprehensive review on three promising strategies. Journal of Drug Delivery Science and Technology, 95, 104375. https://www.sciencedirect.com/science/article/pii/S2274580725001487
7. Nagori, K., et al. (2025). Innovative strategies for overcoming blood-brain barrier challenges in Alzheimer’s disease.Biochimica et Biophysica Acta (BBA) — Molecular Basis of Disease, 1874(3), 166634. https://www.sciencedirect.com/science/article/pii/S1387700324015946

Until next time ❤

— Negin & Amirali